Nexavar improves survival in liver cancer

Published: 2010-10-06 06:53:00

Updated: 2010-10-06 06:53:00

According to a press release from Bayer Healthcare, which was held to mark the 5-year launching of Nexavar (sorafenib) in Korea, the medication appears to improve overall survival among patients with hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) who have not received prior therapy.

Nexavar is an oral multi-kinase inhibitor that targets both the tumor cell and tumor vasculatur...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.